Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure. (2025). SKIN The Journal of Cutaneous Medicine, 9(1), s511. https://doi.org/10.25251/skin.9.supp.511